Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00345358 |
The purpose of this phase IIIb study is to determine whether children who have not received a 3-dose primary vaccination with the pneumococcal conjugate vaccine before their 6 months of age, can receive the vaccine as part of a catch-up immunization schedule. The immunogenicity, safety and reactogenicity of GSK Biologicals' pneumococcal conjugate vaccine will be evaluated for four different age groups with different schedules:
< 6 months of age group: 3-dose primary vaccination + a booster dose. 7 to 11 months of age group: 2-dose primary vaccination + a booster dose. 12 to 23 months of age group: 2-dose vaccination; no booster dose. 24 months to 5 years of age group: 1-dose vaccination; no booster dose. Children below 6 months of age will receive concomitantly a DTPa-IPV/Hib vaccine.
Condition | Intervention | Phase |
---|---|---|
Pneumococcal Disease |
Biological: Pneumococcal conjugate vaccine GSK1024850A. Biological: Infanrix IPV/Hib |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Non-Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Evaluate Immunogenicity, Safety & Reactogenicity of GSK Biologicals' 10-Valent Pneumococcal Conjugate Vaccine Given as Catch-up Immunization in Children Older Than 7 mo of Age or as 3-Dose Primary Immunization in Children Before 6 mo of Age |
Enrollment: | 600 |
Study Start Date: | September 2006 |
Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
<6 Mo: Active Comparator
Children of 9-12 weeks of age at the time of first vaccination receiving 3-dose primary vaccination of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix IPV/Hib) at 3-4-5 months of age and a booster dose at 12-15 months of age.
|
Biological: Pneumococcal conjugate vaccine GSK1024850A.
1, 2, 3 or 4 Intramuscular injections, depending on age group
Biological: Infanrix IPV/Hib
4 intramuscular injections
|
12-23 Mo: Experimental
Children between 12 to 23 months of age at the time of first vaccination receiving 2-dose primary vaccination of pneumococcal conjugate vaccine GSK1024850A with at least 8 weeks interval
|
Biological: Pneumococcal conjugate vaccine GSK1024850A.
1, 2, 3 or 4 Intramuscular injections, depending on age group
|
>=24 Mo: Experimental
Children between 24 months to 5 years of age at the time of first vaccination receiving single dose of pneumococcal conjugate vaccine GSK1024850A
|
Biological: Pneumococcal conjugate vaccine GSK1024850A.
1, 2, 3 or 4 Intramuscular injections, depending on age group
|
7-11 Mo: Experimental
Children between 7 to 11 months of age at the time of first vaccination receiving 2-dose primary vaccination of pneumococcal conjugate vaccine GSK1024850A with at least 4 weeks interval and a booster dose at 12-15 months
|
Biological: Pneumococcal conjugate vaccine GSK1024850A.
1, 2, 3 or 4 Intramuscular injections, depending on age group
|
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007
Ages Eligible for Study: | 9 Weeks to 5 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Male or female between, and including
Exclusion Criteria:
Finland | |
GSK Investigational Site | |
Helsinki, Finland, 00930 | |
GSK Investigational Site | |
Espoo, Finland, 02100 | |
GSK Investigational Site | |
Vantaa, Finland, 01600 | |
GSK Investigational Site | |
Helsinki, Finland, 00100 | |
GSK Investigational Site | |
Vantaa, Finland, 01300 | |
GSK Investigational Site | |
Kotka, Finland, 48600 | |
GSK Investigational Site | |
Tampere, Finland, 33100 | |
GSK Investigational Site | |
Jarvenpaa, Finland, 04400 | |
GSK Investigational Site | |
Seinajoki, Finland, 60100 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 107058 |
Study First Received: | June 27, 2006 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00345358 |
Health Authority: | Czech Republic: State Institute for Drug Control |
Pneumococcal vaccine Pneumococcal disease Safety |
Immunogenicity Booster vaccination Catch-up vaccination |